Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE I KARSH

Allopathic & Osteopathic Physicians Urology

NPI
1194766279
CMS profile
280656
Location
DENVER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$131,398.42

179 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE I KARSH

NPI 1194766279 · CMS profile ID 280656

Allopathic & Osteopathic Physicians / Urology

DENVER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194766279?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE I KARSH, NPI 1194766279, CMS profile ID 280656. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194766279?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LAWRENCE I KARSH, NPI 1194766279, CMS profile ID 280656. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194766279?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LAWRENCE I KARSH, NPI 1194766279, CMS profile ID 280656, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1194766279?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

179 matching records · $131,398.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 179 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 179.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $2.3210/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516085 CMS
Janssen Biotech, Inc. $14.9910/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516073 CMS
PFIZER INC. $330.0010/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673846831 CMS
PFIZER INC. $4,845.0010/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673020835 CMS
AstraZeneca Pharmaceuticals LP $2,700.0010/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685132141 CMS
AstraZeneca Pharmaceuticals LP $1,611.0010/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685450991 CMS
Astellas Pharma US Inc $22.1710/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655629027 CMS
Janssen Biotech, Inc. $69.6010/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516069 CMS
Janssen Biotech, Inc. $1.7210/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516065 CMS
Janssen Biotech, Inc. $12.3110/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516063 CMS
Astellas Pharma US Inc $16.2210/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655629023 CMS
Janssen Biotech, Inc. $4,100.0010/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516059 CMS
Bayer HealthCare Pharmaceuticals Inc. $5,200.0010/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628466775 CMS
Bayer HealthCare Pharmaceuticals Inc. $3,120.0010/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628467091 CMS
AstraZeneca Pharmaceuticals LP $69.6009/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685261821 CMS
AstraZeneca Pharmaceuticals LP $78.3909/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685636871 CMS
Bayer HealthCare Pharmaceuticals Inc. $22.7109/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628426359 CMS
AstraZeneca Pharmaceuticals LP $52.0509/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685508801 CMS
Janssen Biotech, Inc. $217.8109/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516055 CMS
Janssen Biotech, Inc. $59.9709/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516051 CMS
AstraZeneca Pharmaceuticals LP $1,250.0009/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685830875 CMS
Astellas Pharma US Inc $3,325.0009/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655629017 CMS
Astellas Pharma US Inc $28.6009/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655629019 CMS
Bayer HealthCare Pharmaceuticals Inc. $69.3509/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628483345 CMS
Bayer HealthCare Pharmaceuticals Inc. $74.4309/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628472001 CMS
Bayer HealthCare Pharmaceuticals Inc. $74.4309/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628492557 CMS
Endo Pharmaceuticals Inc. $15.2509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685076673 CMS
Astellas Pharma US Inc $17.3309/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655629013 CMS
PFIZER INC. $11.5009/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673293671 CMS
Janssen Biotech, Inc. $4,040.0008/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516047 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,550.0008/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628490203 CMS
Bayer HealthCare Pharmaceuticals Inc. $108.6508/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628425703 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.6508/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628471079 CMS
Bayer HealthCare Pharmaceuticals Inc. $13.0008/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628480131 CMS
Bayer HealthCare Pharmaceuticals Inc. $30.0008/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628492443 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,550.0008/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628480903 CMS
Janssen Biotech, Inc. $33.1608/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516035 CMS
Janssen Biotech, Inc. $28.4208/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516039 CMS
Janssen Biotech, Inc. $47.3708/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516043 CMS
Janssen Biotech, Inc. $731.8908/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516031 CMS
Dendreon Pharmaceuticals LLC $29.7108/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703763593 CMS
Janssen Pharmaceuticals, Inc $8.5408/14/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658814243 CMS
Astellas Pharma US Inc $8.4208/01/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655629007 CMS
Astellas Pharma US Inc $15.4108/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655629009 CMS
COMSORT, Inc $100.0008/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804673 CMS
Endo Pharmaceuticals Inc. $18.9707/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685076669 CMS
Janssen Biotech, Inc. $500.0007/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658516028 CMS
Amgen Inc. $17.4507/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662629763 CMS
Astellas Pharma US Inc $124.8107/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655629003 CMS
PFIZER INC. $15.5207/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672309785 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $131,398.42 179
PY2020 $87,159.87 97
PY2021 $103,405.70 104
PY2022 $119,553.97 146
PY2023 $127,061.51 151
PY2024 $76,352.84 68
PY2025 $61,527.00 59

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,210.00 3
PY2025 Principal investigator $1,397,669.97 141
PY2024 Recipient $8,120.00 9
PY2024 Principal investigator $955,667.13 105
PY2023 Recipient $5,875.67 11
PY2023 Principal investigator $783,568.93 158
PY2022 Recipient $3,499.06 2
PY2022 Principal investigator $1,384,612.39 192
PY2021 Recipient $5,066.33 4
PY2021 Principal investigator $1,601,811.00 172
PY2020 Recipient $4,732.50 7
PY2020 Principal investigator $1,691,275.92 248
PY2019 Principal investigator $1,133,326.18 201

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

144 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $46,207.89 12/30/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726486
Principal investigator 1 MEDIVATION LLC. $1,143.45 12/24/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228740712
Principal investigator 1 Janssen Research & Development, LLC $381.00 12/18/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175416199
Principal investigator 1 Janssen Research & Development, LLC $311.00 12/18/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416267
Principal investigator 1 Janssen Research & Development, LLC $224.00 12/18/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175416296
Principal investigator 1 Janssen Research & Development, LLC $509.04 12/12/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416195
Principal investigator 1 Janssen Research & Development, LLC $910.00 11/24/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416217
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $877.50 11/12/2025 Non-covered Recipient Entity
The Urology Center Of Colorado
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225419731
Principal investigator 1 Sumitomo Pharma America, Inc. $1,225.50 11/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654686
Principal investigator 1 Sumitomo Pharma America, Inc. $450.00 11/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654792
Principal investigator 1 Sumitomo Pharma America, Inc. $15.00 11/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654891
Principal investigator 1 Sumitomo Pharma America, Inc. $4,941.00 11/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654946
Principal investigator 1 Sumitomo Pharma America, Inc. $15.00 11/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176655060
Principal investigator 1 MEDIVATION LLC. $1,312.20 11/04/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739566
Principal investigator 1 MEDIVATION LLC. $1,143.45 11/04/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228748014
Principal investigator 1 PFIZER INC. $26,929.00 11/04/2025 Non-covered Recipient Entity
Adventist Health SystemSunbelt Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228739334
Principal investigator 1 PFIZER INC. $46,207.89 11/03/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727161
Principal investigator 1 PFIZER INC. $46,207.89 10/31/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723842
Principal investigator 1 Janssen Research & Development, LLC $2,339.00 10/27/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416272
Principal investigator 1 Janssen Research & Development, LLC $976.00 10/13/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175416206
Principal investigator 1 PFIZER INC. $46,207.89 10/13/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726622
Principal investigator 1 PFIZER INC. $46,207.89 10/11/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228725822
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $438.75 10/10/2025 Non-covered Recipient Entity
The Urology Center Of Colorado
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225419701
Principal investigator 1 MEDIVATION LLC. $1,143.45 10/01/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739372
Principal investigator 1 MEDIVATION LLC. $1,143.45 10/01/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228746561
Principal investigator 1 Janssen Research & Development, LLC $580.00 09/19/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416300
Principal investigator 1 Janssen Research & Development, LLC $336.00 09/08/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175416278
Principal investigator 1 MEDIVATION LLC. $1,143.45 09/01/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228743263
Principal investigator 1 Janssen Research & Development, LLC $641.00 08/25/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416289
Principal investigator 1 Janssen Research & Development, LLC $869.00 08/18/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175416254
Principal investigator 1 MEDIVATION LLC. $1,143.45 08/15/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228742936
Principal investigator 1 MEDIVATION LLC. $1,143.45 08/15/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228743072
Principal investigator 1 MEDIVATION LLC. $1,143.45 08/15/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228743316
Principal investigator 1 PFIZER INC. $30,805.26 08/13/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727397
Principal investigator 1 PFIZER INC. $30,805.26 08/12/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726620
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 08/01/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641706
Principal investigator 1 Sumitomo Pharma America, Inc. $1,225.50 08/01/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641741
Principal investigator 1 Sumitomo Pharma America, Inc. $15.00 08/01/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641827
Principal investigator 1 Janssen Research & Development, LLC $1,429.00 07/24/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416239
Principal investigator 1 Sumitomo Pharma America, Inc. $1,225.50 07/09/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640397
Principal investigator 1 Janssen Research & Development, LLC $1,118.00 06/30/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416185
Principal investigator 1 Janssen Research & Development, LLC $10,370.10 06/18/2025 Non-covered Recipient Entity
The Uro Ctr Of Colorado Computed Tomography
A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1175183812
Principal investigator 1 Janssen Research & Development, LLC $500.00 06/16/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175416315
Principal investigator 1 Janssen Research & Development, LLC $107.00 06/13/2025 Non-covered Recipient Entity
The Uro Ctr Of Colorado
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175183641
Principal investigator 1 Janssen Research & Development, LLC $1,490.00 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416223
Principal investigator 1 MEDIVATION LLC. $251.10 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723960
Principal investigator 1 MEDIVATION LLC. $1,143.45 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228781326
Principal investigator 1 MEDIVATION LLC. $251.10 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790146
Principal investigator 1 MEDIVATION LLC. $251.10 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790510
Principal investigator 1 MEDIVATION LLC. $251.10 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791464
Principal investigator 1 MEDIVATION LLC. $251.10 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791595
Principal investigator 1 MEDIVATION LLC. $251.10 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792433
Principal investigator 1 MEDIVATION LLC. $251.10 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793114
Principal investigator 1 MEDIVATION LLC. $1,143.45 06/02/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793320
Principal investigator 1 Janssen Research & Development, LLC $381.00 05/29/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175416282
Principal investigator 1 PFIZER INC. $138,618.36 05/14/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753471
Principal investigator 1 PFIZER INC. $138,618.36 05/13/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753829
Principal investigator 1 PFIZER INC. $138,623.67 05/13/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754331
Principal investigator 1 Sumitomo Pharma America, Inc. $15.00 05/07/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634282
Principal investigator 1 Sumitomo Pharma America, Inc. $28,363.50 05/07/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634301
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228719759
Principal investigator 1 MEDIVATION LLC. $251.10 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789909
Principal investigator 1 MEDIVATION LLC. $251.10 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790130
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790303
Principal investigator 1 MEDIVATION LLC. $1,312.20 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790366
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790595
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791146
Principal investigator 1 MEDIVATION LLC. $251.10 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791344
Principal investigator 1 MEDIVATION LLC. $590.63 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791431
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791455
Principal investigator 1 MEDIVATION LLC. $251.10 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791593
Principal investigator 1 MEDIVATION LLC. $251.10 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791606
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791704
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792048
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792122
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792156
Principal investigator 1 MEDIVATION LLC. $251.10 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792476
Principal investigator 1 MEDIVATION LLC. $251.10 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792685
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792692
Principal investigator 1 MEDIVATION LLC. $251.10 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792789
Principal investigator 1 MEDIVATION LLC. $251.10 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793427
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793667
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793757
Principal investigator 1 MEDIVATION LLC. $1,143.45 05/05/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793999
Principal investigator 1 Janssen Research & Development, LLC $1,387.00 04/28/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416244
Recipient PFIZER INC. $940.00 04/27/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770986
Principal investigator 1 BioXcel Therapeutics, Inc. $613.54 04/04/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
BXCL-701-201 No dispute reported 06/30/2026 1228697961
Principal investigator 1 PFIZER INC. $46,206.12 04/02/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751909
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228719793
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228719971
Principal investigator 1 MEDIVATION LLC. $43.75 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228720183
Principal investigator 1 MEDIVATION LLC. $43.75 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723564
Principal investigator 1 MEDIVATION LLC. $43.75 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228779595
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228780853
Principal investigator 1 MEDIVATION LLC. $251.10 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228781185
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789846
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789955
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789974
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790065
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790269
Principal investigator 1 MEDIVATION LLC. $43.75 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790296
Principal investigator 1 MEDIVATION LLC. $251.10 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790701
Principal investigator 1 MEDIVATION LLC. $590.63 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790787
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790892
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790907
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791028
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791257
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791331
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791373
Principal investigator 1 MEDIVATION LLC. $43.75 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791490
Principal investigator 1 MEDIVATION LLC. $18.60 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791656
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791785
Principal investigator 1 MEDIVATION LLC. $251.10 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791926
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791966
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792051
Principal investigator 1 MEDIVATION LLC. $18.60 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792415
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792584
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792629
Principal investigator 1 MEDIVATION LLC. $43.75 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792633
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792757
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792845
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792914
Principal investigator 1 MEDIVATION LLC. $72.30 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793329
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793499
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793640
Principal investigator 1 MEDIVATION LLC. $43.75 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793657
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793764
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793769
Principal investigator 1 MEDIVATION LLC. $18.60 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793778
Principal investigator 1 MEDIVATION LLC. $84.70 04/01/2025 Non-covered Recipient Entity
THE UROLOGY CENTER OF COLORADO
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793996
Principal investigator 1 PFIZER INC. $46,206.12 04/01/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753128
Principal investigator 1 PFIZER INC. $46,207.89 04/01/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228758009
Principal investigator 1 Janssen Research & Development, LLC $488.00 03/31/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175416191
Principal investigator 1 Janssen Research & Development, LLC $538.00 03/27/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416250
Principal investigator 1 Janssen Research & Development, LLC $107.00 03/14/2025 Non-covered Recipient Entity
The Uro Ctr Of Colorado
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175183594
Principal investigator 1 Janssen Research & Development, LLC $891.00 02/24/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416309
Principal investigator 1 Janssen Research & Development, LLC $2,732.00 02/03/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175416212
Principal investigator 1 Janssen Research & Development, LLC $112.00 02/03/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175416230
Principal investigator 1 Janssen Research & Development, LLC $976.00 02/03/2025 Non-covered Recipient Entity
PORTERCARE ADVENTIST HEALTH SYSTEM
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175416261
Recipient PFIZER INC. $940.00 02/03/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751995
Recipient PFIZER INC. $330.00 01/15/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769929
Principal investigator 1 PFIZER INC. $138,623.67 01/09/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228722722
Principal investigator 1 PFIZER INC. $138,618.36 01/09/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753459
Principal investigator 1 PFIZER INC. $138,618.36 01/09/2025 Non-covered Recipient Entity
Advent Health Medical Group Urology Denver
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753467

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.01 1
PY2025 Value of interest $0.01 1
PY2024 Amount invested $0.01 1
PY2024 Value of interest $0.01 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $0.01 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

3 records · PY2023–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 SWAN VALLEY MEDICAL INCORPORATED $0.01 $0.01 These shares were purchased or granted in past years. This is only to update the value of ownership, which is currently zero. The company is privately held with no public market for the sale of shares so as we stand at the end of 2025, the shares the doctors own are without value. Physician Covered Recipient No dispute reported 06/30/2026 1205963608
PY2024 SWAN VALLEY MEDICAL INCORPORATED $0.01 $0.01 These shares were purchased or granted in past years. This is only to update the value of ownership, which is currently zero. The company is privately held with no public market for the sale of shares so as we stand at the end of 2024, the shares the doctors own are without value. Physician Covered Recipient No dispute reported 06/30/2026 1126752480
PY2023 SWAN VALLEY MEDICAL INCORPORATED $0.00 $0.01 Shares listed were purchased or granted for services in past reported years. The current value of these shares is the par value of $0.01. The Company is a privately held C Corporation with no public market for the sale of its highly restricted stock. The Company is has never been profitable and its liabilities currently exceed its assets, with operating expenses exceeding its sales revenues. Physician Covered Recipient No dispute reported 06/30/2026 984043599